Review Article

Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis

Authors: Tracey D. Dabal, MD, Matthew B. Haltom, MD, Puja P. Patel, DO, Christine K. Son, MD, Kiran P. Joglekar, MD, Charles M. Groeschell, MD, Mason M. Chumpia, MD, Sehrish F. Kamal, MD, Ankur Seth, MD, Christopher D. Jackson, MD

Abstract

Objective: We evaluated the safety of baricitinib 4 mg at 24 weeks for the treatment of moderate to severe rheumatoid arthritis (RA).

Methods: Multiple databases were searched from inception up to November 26, 2019 for randomized controlled trials comparing baricitinib 4 mg with placebo for the treatment of moderate to severe RA. The safety outcomes of interest were the incidence of serious adverse events, adverse events leading to study discontinuation, all infections, and serious infections. Adjusted risk ratios (RRs) with 95% confidence intervals (CIs) were pooled for safety outcomes. The Cochrane tool was used to assess the risk of bias.

Results: This analysis included four randomized controlled trials with 3106 patients. For serious adverse events, the pooled RR (95% CI) was 1.09 (0.76–1.57). For adverse events leading to study discontinuation, the pooled RR (95% CI) was 1.41 (0.94–2.11). For all reported infections, the pooled RR (95% CI) was 1.24 (1.10–1.40), For serious infections, pooled RR (95% CI) was 0.97 (0.51–2.57).

Conclusions: Patients with RA taking 4 mg baricitinib daily did have an increased risk of infections; however, the incidence of serious adverse events, adverse events leading to study discontinuation, or serious infections were not significantly different in patients treated with baricitinib 4 mg compared with placebo.
Posted in: Rheumatology and Orthopedics14

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Fazal SA, Khan M, Nishi SE, et al. A clinical update and global economic burden of rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets 2018;18:98–109.
 
2. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293–322.
 
3. O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72(suppl 2):ii111–5.
 
4. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
 
5. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243–1252.
 
6. Fleischmann R, Schiff M, Van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506–517.
 
7. Dougados M, Van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88–95.
 
8. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652–662.
 
9. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755–1766.
 
10. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf 2018;41:645–653.
 
11. Eli Lilly and Company. FDA Briefing Document. Arthritis Advisory Committee Meeting, April 23, 2018. NDA 207924, Baricitinib Janus Kinase (JAK) inhibitor for RA. https://www.fda.gov/media/112372/download. Published 2018. Accessed February 28, 2021.
 
12. Wu ZP, Zhang P, Bai JZ, et al. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: a meta-analysis of randomized controlled trials. Exp Ther Med 2018;16:2449–2459.
 
13. Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol 2018;37:2611–2620.
 
14. Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14–21.